The clinical significance of serum KL-6 levels in patients with type C liver diseases

Hepatology Research

Volumn 25, Issue 4, 2003, Pages 385-395

  Moriyama, Mitsuhiko ^a   Matsumura, Hiroshi ^a   Mikuni, Morio ^a   Arkawa, Yasuo ^a   Ohshiro, Shuh ^a   Aoki, Hiroshi ^a   Yamagami, Hiroaki ^a   Kaneko, Miki ^a   Shioda, Atsuo ^a   Saito, Hiroshi ^a   Tanaka, Naohide ^a   Arakawa, Yasuyuki ^a  

^a NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Hepatocellular carcinoma; Irregular regeneration of hepatocytes; KL 6; Liver cirrhosis; Type C chronic hepatitis

Indexed keywords

ALANINE AMINOTRANSFERASE; MUCIN 1;

ADULT; ARTICLE; ASSAY; BLOOD SAMPLING; CANCER SCREENING; CANCER STAGING; CELL REGENERATION; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE CLASSIFICATION; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FROZEN SECTION; HEPATITIS C; HEPATITIS C VIRUS; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; INCIDENCE; LIVER BIOPSY; LIVER CELL; LIVER CELL CARCINOMA; LIVER DISEASE; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCREENING TEST;

EID: 0037398867     PISSN: 13866346     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1386-6346(02)00307-8     Document Type: Article

References (26)

1. Kohno N, Akiyama M, Kyoizumi S, Hakoda M, Kobuke K, Yamakido M. Detection of soluble tumor-associated antigens in sera and effusions using novel monoclonal antibodies, KL-3 and KL-6, against lung adenocarcinoma. Jpn J Clin Oncol 1988;18:203-16.
2. Stahel RA, Hilks WR, Lehmann HP, Schenker T. Third international workshop on lung tumor and differentiation antigens: overview of the results of the central data analysis. Int J Cancer 1994;8(Suppl.):6-26.
3. Kohno N, Kyoizumi S, Awaya Y, Fukuhara H, Yamakido M, Akiyama M. New serum indicator of interstitial pneumonitis activity. sialylated carbohydrate antigen KL-6. Chest 1989;96:68-73.
4. Kohno N, Koizumi S, Tanabe M, et al. Detection of a circulating tumor associated antigen with a murine monoclonal antibody, LISA 101, selected by reversed indirect enzyme-linked immunosorbent assay. Cancer Res 1989;49:3412-9.
5. Hamada H, Kohno N, Akiyama M, Hiwada K. Monitoring of serum KL-6 antigen in a patient with radiation pneumonia. Chest 1992;101:858-60.
6. Kobayashi J, Kitamura S. Serum KL-6 for the evaluation of active pneumonitis in pulmonary sarcoidosis. Chest 1996;109:1276-83.
7. Inoue Y, Nishimura K, Shiode M, et al. Evaluation of serum KL-6 levels in patients with pulmonary tuberculosis. Yuber Lung Dis 1995;96:230-3.
8. LeRoy EC, Black C, Fleischmajer R, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988;15:202-6.
9. Yamane K, Ihn H, Kubo M, et al. Serum levels of KL-6 as a useful marker for evaluating pulmonary fibrosis with systemic sclerosis. J Rheumatol 2000;27:930-4.
10. Bandoh S, Fujita J, Ohtsuki Y, et al. Sequential changes of KL-6 in sera of patients with interstitial pneumonia associated with polymyositis/dermatomyositis. Ann Rheum Dis 2000;59:257-62.
11. Kubo M, Ihn K, Yamane K, et al. Serum KL-6 in adult patients with polymyositis and dermatomyositis. Rheumatology 2000;39:632-6.
12. Kohno N, Hamada H, Fujioka S, Hiwada K, Yamakido M, Akiyama M. Circulating antigen KL-6 and lactate dehydrogenase for monitorling irradiated patients with lung cancer. Chest 1992;102:117-22.
13. Kohno N. Serum marker KL-6/MUC1 for the diagnosis and management of interstitial pneumonia. J Med Invest 1999;49:151-8.
14. Yoshida H, Shiratori Y, Moriyama M, et al. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. Ann Intern Med 1999;131:174-81.
15. Matsumura H, Moriyama M, Goto I, Tanaka N, Ohkubo H, Arakawa Y. Natural course of progression of liver fibrosis in patients with chronic liver disease type C in Japan-a study of 527 patients at one establishment in Japan. J Viral Hepat 2000;7:268-75.
16. Nasuno K, Moriyama M, Matsumura H, et al. The clinical significance of the determination of serum KL-6 levels in patients with chronic liver disease. Hepatology 2000;32:281A.
17. Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 1994;19:1513-20.
18. Matsumura H, Moriyama M, Tanaka N, Okubo H, Uchida T, Arakawa Y. The serum hepatitis C virus RNA at two weeks after the administration of interferon: its predictability for the efficacy of interferon treatment for chronic hepatitis C. Nihon Univ J Med 1998;40:61-9.
19. Watanabe K, Nishimura J, Ito K, et al. Development of an EIA kit (ED046) for the determination of serum KL-6 levels and an investigation of test conditions for this kit. Respiration 1996;15:912-7 (in Japanese).
20. Okamoto H, Sugiyama Y, Okada S, et al. Typing of hepatitis C virus by PCR with type-specific primers: application to clinical surveys and tracing infectious sources. J Gen Virol 1992;73:673-9.
21. Simmonds P, Alberti A, Alter J, et al. A proposed system for the nomenclature of hepatitis C viral genotypes. Hepatology 1994;19:1321-4.
22. Uchida T. Small hepatocellular carcinoma: Its relationship to multistep hepatocarcinogenesis. Pathol Int 1995;45:175-84.
23. Uchida T. Pathology of hepatitis C. Intervirology 1994;37:126-32.
24. Shibata M, Morizane T, Uchida T, et al. Irregular regeneration of hepatocytes and risk of hepatocellular carcinoma in chronic hepatitis and cirrhosis with hepatitis-C-virus infection. Lancet 1998;351:1773-7.
25. Ueno Y, Moriyama M, Uchida T, Arakawa Y. Irregular regeneration of hepatocytes is an important factor in the hepatocarcinogenesis of liver disease. Hepatology 2001;33:357-62.
26. Moriyama M, Okubo H, Suzuki K, Tanaka N, Arakawa Y. Serial observation of irregular regeneration of hepatocytes in the rat livers administrated with a chemical carcinogen, Diethylnitrosamine (DEN). Hepatology 1999;30:560A.